CARDIOVASCULAR JOURNAL OF AFRICA • Volume 35, No 1, January – April 2024 AFRICA 25 1731–1736. 22. Figulla HR, Webb JG, Lauten A, Feldman T. The transcatheter valve technology pipeline for treatment of adult valvular heart disease. Eur Heart J 2016; 37(28): 2226–2239. 23. Das P, Prendergast B. Imaging in mitral stenosis: assessment before, during and after percutaneous balloon mitral valvuloplasty. Expert Rev Cardiovasc Ther 2003; 1(4): 549–557. 24. Lang RM, Badano LP, Victor MA, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28(1): 1–39.e14. 25. Hahn RT, Abraham T, Adams MS, Bruce CJ, Glas KE, Lang RM, et al. Guidelines for performing a comprehensive transesophageal echocardiographic examination: Recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. J Am Soc Echocardiogr 2013; 26(9): 921–964. 26. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62(25). 27. Palacios IF. Percutaneous mitral balloon valvuloplasty – state of the art. Mini-invasive Surg 2020; 2020: 1–24. 28. Lau K‐W, Hung J‐S. A simple balloon‐sizing method in Inoue‐balloon percutaneous transvenous mitral commissurotomy. Cathet Cardiovasc Diagn 1994; 33(2): 120–129. 29. Elangovan C, Rajaskhar RD, Prathap KG, Swaminathan N, Gnanavelu G, Ravishankar G. Rheumatic mitral stenosis with left atrial appendage thrombus – Effect of oral anticoagulation on left atrial appendage thrombus resolution. Indian J Res 2018; 7(7): 37–41. 30. Kaymaz C, Özdemir N, Erentuǧ V, Şişmanoǧlu M, Yakut C, Özkan M. Location, size, and morphologic characteristics of left atrial thrombi as assessed by transesophageal echocardiography in relation to systemic embolism in patients with rheumatic mitral valve disease. Am J Cardiol 2003; 91(6): 765–769. 31. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol 1994; 23(4): 961–969. 32. González-Torrecilla E, García-Fernández MA, Pérez-David E, Bermejo J, Moreno M, Delcán JL. Predictors of left atrial spontaneous echo contrast and thrombi in patients with mitral stenosis and atrial fibrillation. Am J Cardiol 2000; 86(5): 529–534. 33. Shrestha NK, Moreno FL, Narciso FV, Torres L, Calleja HB. Two-dimensional echocardiographic diagnosis of left atrial thrombus in rheumatic heart disease. A clinicopathologic study. Circulation 1983; 67(2): 341–347. 34. Vincelj J, Sokol I, Jakšić O. Prevalence and clinical significance of left atrial spontaneous echo contrast detected by transesophageal echocardiography. Echocardiography 2002; 19(4): 319–324. 35. Black IW. Spontaneous echo contrast: Where there’s smoke there’s fire. Echocardiography 2000; 17(4): 373–382. 36. Hung JS. Mitral stenosis with left atrial thrombi: Inoue balloon catheter technique. In: Cheng TO, ed. Percutaneous Balloon Valvuloplasty. New York: Igaku-Shoin, 1992: 280–293. 37. Renda G, Ricci F, Giugliano RP, De Caterina R. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. J Am Coll Cardiol 2017; 69(11): 1363–1371. 38. Briasoulis A, Inampudi C, Akintoye E, Alvarez P, Panaich S, VaughanSarrazin M. Safety and efficacy of novel oral anticoagulants versus warfarin in medicare beneficiaries with atrial fibrillation and valvular heart disease. J Am Heart Assoc 2018; 7(8). 39. Fanaroff AC, Vora AN, Lopes RD. Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease. Eur Hear J 2022; 24(Suppl A): A19–31. 40. Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, et al. Rivaroxaban in Rheumatic heart disease-associated atrial fibrillation. N Engl J Med 2022: 1–11. 41. Yuyun MF, Bonny A, Ng GA, Sliwa K, Pascal A, Chin A, et al. A systematic review of the spectrum of cardiac arrhythmias in sub-Saharan Africa. Glob Heart 2020; 15(1): 37. 42. Mutagaywa RK, Chin A, Karaye K, Bonny A. Unmet needs in the management of arrhythmias among heart failure patients in Africa. Eur Heart J 2022; 43(23): 2170–2172. 43. Abascal VM, Wilkins GT, O’Shea JP, Choong CY, Palacios IF, Thomas JD, et al. Prediction of successful outcome in 130 patients undergoing percutaneous balloon mitral valvotomy. Circulation 1990; 82(2): 448–456. 44. Iung B, Garbarz E, Doutrelant L, Berdah P, Michaud P, Farah B, et al. Late results of percutaneous mitral commissurotomy for calcific mitral stenosis. Am J Cardiol 2000; 85(11): 1308–1314. 45. Almeida R, Paiva M, Correia AS, Lopes R, Gonc A, Almeida PB, et al. Selection of patients for percutaneous balloon mitral valvotomy: Is there a definitive limit for the Wilkins score? Port J Cardiol 2013; 32(11): 873–878. 46. Carvalho MM De, Pinto RA, Proenca T, Calva J, Costa CM Da, Amador A, et al. Long-term success in percutaneous valve commissurotomy – is Wilkins score over 9 a definitive limit? Abstract presentation at the ESC 2022. Available from: https://esc365.escardio.org 47. Suliman AA, Ngunga M, Jeilan M, Mohammed M, Mohamed M. Enhancing cardiovascular skills development in Africa: Khartoum first PTMC workshop. Cardiovasc J Afr 2021; 32(5): 287–288. 48. Ambari AM, Setianto B, Santoso A, Dwiputra B, Cramer MJM, Doevendans PA, et al. Survival analysis of patients with rheumatic MS after PBMV compared with MVS in a low-to-middle-income country. Neth Hear J 2019; 27: 559–564. 49. Den HP. Percutaneous balloon mitral valvuloplasty: is there still a place for it in the Netherlands? Netherl Heart J 2019: 537–540. 50. Mohr FW, Falk V, Diegeler A, Walther T, van Son JAM, Autschbach R. Minimally invasive port-access mitral valve surgery. J Thorac Cardiovasc Surg 1998; 115(3): 567–756. 51. Marijon É, Lung B, Mocumbi AO, Kamblock J, Vo Thanh C, Gamra H, et al. What are the differences in presentation of candidates for percutaneous mitral commissurotomy accross the world and do they influence the results of the procedure? Arch Cardiovasc Dis 2008; 101(10): 611–617. 52. Mvondo CM, Pugliese M, Giamberti A, Chelo D, Kuate LM, Boombhi J, et al. Surgery for rheumatic mitral valve disease in sub-saharan African countries: Why valve repair is still the best surgical option. Pan Afr Med J 2016; 24: 1–8. 53. Turina MI. European Association for Cardio-Thoracic Surgery: carrying the torch. Eur J Cardio-thoracic Surg 2002; 22: 857–863. 54. Cohen D, Kuntz R, Gordon S, Piana RN, Safian RD. Predictors of long-term outcome after percutaneous balloon mitral valvuloplasty. N Engl J Med 1992; 327(19). 55. Vahanian A, Himbert D, Brochet E, Iung B. Percutaneous mitral commissurotomy. In: Ziyad M. Hijazi, Ted Feldman, John Cheatham, Horst Sievert (eds). Complications During Percutaneous Interventions for Congenital and Structural Heart Diseases. 1st edn. London: CRC Press, 2009: 388. Available from: https://doi.org/10.3109/9780203092118 56. Zühlke L, Mayosi BM. Echocardiographic screening for subclinical rheumatic heart disease remains a research tool pending studies of
RkJQdWJsaXNoZXIy NDIzNzc=